Search for a clinical trial
Other search option(s)
10 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
GERMANY
Bayern
MÜNCHEN
SynCoRAS: Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders (GeNeRARe study)
TUM Fakultät für Medizin
GERMANY
Bayern
MÜNCHEN
SynCoRAS: Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders (GeNeRARe study)
kbo-Kinderzentrum München gemeinnützige GmbH
kbo-Kinderzentrum München
NETHERLANDS
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
NETHERLANDS
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Neurowetenschappen
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult and pediatric participants with neurofibromatosis type 1 - ES
Institution: Information not provided - ES
SWEDEN
Region Skĺne
LUND
plexifpc - Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain Relief - SE
Skĺne University Hospital, Lund
UNITED KINGDOM
Greater London
LONDON
A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
NETHERLANDS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ITALY
LAZIO
ROMA